步长制药
(603858)
| 流通市值：200.16亿 | | | 总市值：200.16亿 |
| 流通股本：10.55亿 | | | 总股本：10.55亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 5,663,836,253.89 | 2,784,946,981.48 | 11,005,794,900.15 | 8,514,403,594.83 |
| 营业收入 | 5,663,836,253.89 | 2,784,946,981.48 | 11,005,794,900.15 | 8,514,403,594.83 |
| 二、营业总成本 | 4,990,838,810.29 | 2,463,700,632.04 | 10,388,210,007.49 | 7,978,935,292.72 |
| 营业成本 | 2,130,994,967.96 | 1,063,955,134.14 | 4,427,650,741.4 | 3,650,734,503.88 |
| 税金及附加 | 84,252,129.22 | 44,733,034.13 | 159,019,064.85 | 122,823,188.06 |
| 销售费用 | 2,239,340,547.33 | 1,090,082,446.58 | 4,323,174,318.36 | 3,271,091,901.53 |
| 管理费用 | 394,727,994.4 | 192,314,068.59 | 1,010,181,015.43 | 664,107,114.37 |
| 研发费用 | 84,196,636.41 | 45,145,869.88 | 345,408,287.11 | 180,201,501.97 |
| 财务费用 | 57,326,534.97 | 27,470,078.72 | 122,776,580.34 | 89,977,082.91 |
| 其中:利息费用 | 59,869,654.26 | 28,740,161.81 | 129,588,548.4 | 94,771,086.77 |
| 其中:利息收入 | 3,148,463.53 | 1,590,764.01 | 7,525,042.23 | 5,563,587.71 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 3,377,528.63 | 2,075,377.83 | -149,331.32 | -779,841.27 |
| 加:投资收益 | 4,570,467.9 | -608,269.39 | 13,020,046.98 | 7,470,994.07 |
| 资产处置收益 | 157,220.65 | 161,548.95 | 427,415.37 | 23,475.93 |
| 资产减值损失(新) | 2,601,071.04 | 2,314,194.22 | -977,512,390.37 | -28,058,529.53 |
| 信用减值损失(新) | 34,276,981.07 | 26,440,575.02 | 22,585,406.01 | 17,920,065.2 |
| 其他收益 | 49,767,597.12 | 31,185,034.75 | 77,289,783.6 | 62,865,604.77 |
| 四、营业利润 | 767,748,310.01 | 382,814,810.82 | -246,754,177.07 | 594,910,071.28 |
| 加:营业外收入 | 1,727,186.77 | 1,278,138.54 | 4,924,813.43 | 2,857,426.76 |
| 减:营业外支出 | 19,883,951.03 | 7,964,368.91 | 123,462,199.87 | 95,921,644.03 |
| 五、利润总额 | 749,591,545.75 | 376,128,580.45 | -365,291,563.51 | 501,845,854.01 |
| 减:所得税费用 | 159,362,361.9 | 86,238,376.36 | 337,103,089.74 | 283,970,021.79 |
| 六、净利润 | 590,229,183.85 | 289,890,204.09 | -702,394,653.25 | 217,875,832.22 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 590,229,183.85 | 289,890,204.09 | -702,394,653.25 | 217,875,832.22 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 627,701,257.33 | 307,261,088.17 | -553,797,938.8 | 312,863,200.9 |
| 少数股东损益 | -37,472,073.48 | -17,370,884.08 | -148,596,714.45 | -94,987,368.68 |
| 扣除非经常损益后的净利润 | 618,837,568.16 | 299,588,268.04 | -492,701,984.25 | 358,900,124.19 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.59 | 0.29 | -0.51 | 0.29 |
| (二)稀释每股收益 | 0.59 | 0.29 | -0.51 | 0.29 |
| 八、其他综合收益 | 312,653.69 | -935,561.51 | -605,746.2 | -68,691.63 |
| 归属于母公司股东的其他综合收益 | 312,653.69 | -935,561.51 | -605,746.2 | -68,691.63 |
| 九、综合收益总额 | 590,541,837.54 | 288,954,642.58 | -703,000,399.45 | 217,807,140.59 |
| 归属于母公司股东的综合收益总额 | 628,013,911.02 | 306,325,526.66 | -554,403,685 | 312,794,509.27 |
| 归属于少数股东的综合收益总额 | -37,472,073.48 | -17,370,884.08 | -148,596,714.45 | -94,987,368.68 |
| 公告日期 | 2025-08-28 | 2025-04-26 | 2025-04-26 | 2024-10-29 |
| 审计意见(境内) | | | 标准无保留意见 | |